Inside Washington: The Big Shift

Publication
Article
BioPharm InternationalBioPharm International-03-01-2003
Volume 16
Issue 3

Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.